PRL-295
PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD (P) H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen -induced liver injury in mice[1].
Product Specifications
CAS Number
2377770-85-7
UNSPSC
12352005
Target
Aminotransferases (Transaminases) ; Keap1-Nrf2; Quinone Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/prl-295.html
Smiles
O=C(CN(S(=O)(C1=CC=C(C=C1)OC)=O)C2=NC=C(N(S(=O)(C3=CC=C(C=C3)OC)=O)CC(F)(F)F)C4=C2C=CC=C4)O
Molecular Formula
C27H24F3N3O8S2
Molecular Weight
639.62
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Macrophage Inflammatory Protein 3 alpha (CCL20) Human Gene Knockout Kit (CRISPR)
Colloidal Gold Conjugated Monoclonal Antibody to Herpes Simplex I, 10nm
